Please login to the form below

Not currently logged in
Email:
Password:

cemiplimab

This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.

Sanofi extends growth spurt thanks to Genzyme, Dupixent

Sanofi extends growth spurt thanks to Genzyme, Dupixent

Sanofi is also hoping for a sales kick this year and beyond from Libtayo (cemiplimab), its late entrant in the checkpoint inhibitor category which was approved for cutaneous squamous cell carcinoma

Latest news

  • Sanofi's Darzalex rival scores in myeloma trial Sanofi's Darzalex rival scores in myeloma trial

    It is a late entrant into the immuno-oncology category with its Libtayo (cemiplimab) checkpoint inhibitor, approved by the FDA for cutaneous squamous cell carcinoma last September, although the availability of

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)

  • As France protests, Sanofi takes axe to 670 jobs As France protests, Sanofi takes axe to 670 jobs

    dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

  • Regeneron’s early stage bispecific shows promise Regeneron’s early stage bispecific shows promise

    REGN1979 is being investigated in combination with Regeneron’s newly FDA-approved checkpoint inhibitor Libtayo (cemiplimab-rwlc) in an ongoing phase 1 study.

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics